Clinical trial
Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment…
NCT00080106 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00080106 |
|---|---|
| Title | Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients |
| Official title | A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Antiretroviral Effect of Immunization With the MRK Ad5 HIV-1 Gag Vaccine in HIV-1 Infected Individuals Who Interrupt Antiretroviral Therapy |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological, Other |
| Interventions | MRK Ad5 HIV-1 gag vaccine, Vaccine placebo |
| Enrollment | 114 |
| Start date | Jun 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | May 1, 2011 |
| First posted | Mar 25, 2004 |
| Last update posted | Nov 9, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: